Perceptive Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perceptive Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-172,991	Closed	-$25.2M	–	117
2022 Q2	$25.2M	Sell	172,991 -7,088	-4%	-$1.01M	0.79%	30
2022 Q1	$29.4M	Buy	+180,079	New	+$27.4M	0.59%	42
2019 Q1	–	Sell	-262,241	Closed	-$18.5M	–	107
2018 Q4	$18.5M	Sell	262,241 -935,753	-78%	-$72M	0.7%	37
2018 Q3	$105M	Sell	1,197,994 -648,917	-35%	-$65.3M	2.8%	6
2018 Q2	$182M	Buy	1,846,911 +566,109	+44%	+$56.2M	4.77%	4
2018 Q1	$153M	Sell	1,280,802 -50,000	-4%	-$6.45M	4.27%	5
2017 Q4	$169M	Sell	1,330,802 -458,000	-26%	-$57.5M	5.6%	4
2017 Q3	$210M	Sell	1,788,802 -43,959	-2%	-$3.75M	8.03%	3
2017 Q2	$146M	Buy	1,832,761 +729,286	+66%	+$46.6M	7.36%	3
2017 Q1	$56.6M	Buy	1,103,475 +985,000	+831%	+$45.5M	3.22%	6
2016 Q4	$4.44M	Buy	+118,475	New	+$4.96M	0.32%	61
2014 Q2	–	Sell	-50,000	Closed	-$3.36M	–	121
2014 Q1	$3.36M	Buy	+50,000	New	+$3.87M	0.35%	54

Other funds holding ALNY

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Perceptive Advisors's ALNY Position: Q3 2022 in Review

Perceptive Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 172,991 shares — an estimated $25.2M sold.

Perceptive Advisors first reported a position in ALNY in Q1 2014 and held it in 12 quarters. The position peaked at $210M in Q3 2017. 496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Perceptive Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Perceptive Advisors sold 172,991 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $25.2M.
Perceptive Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Perceptive Advisors's Alnylam Pharmaceuticals position peaked at $210M in Q3 2017.
496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.